Amphastar P
$ 18.45
0.16%
02 Jun - close price
- Market Cap 812,192,000 USD
- Current Price $ 18.45
- High / Low $ 18.67 / 18.10
- Stock P/E 11.10
- Book Value 17.33
- EPS 1.66
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.05 %
- ROE 0.10 %
- 52 Week High 31.26
- 52 Week Low 16.64
About
Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company is headquartered in Rancho Cucamonga, California.
Analyst Target Price
$23.33
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-26 | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-02-27 | 2024-11-06 | 2024-08-07 | 2024-05-08 | 2024-02-28 | 2023-11-08 | 2023-08-08 |
| Reported EPS | 0.42 | 0.73 | 0.93 | 0.85 | 0.74 | 0.92 | 0.96 | 0.94 | 1.04 | 0.88 | 1.15 | 0.65 |
| Estimated EPS | 0.71 | 0.9251 | 0.83 | 0.74 | 0.69 | 0.9383 | 0.98 | 0.75 | 0.96 | 0.91 | 0.69 | 0.56 |
| Surprise | -0.29 | -0.1951 | 0.1 | 0.11 | 0.05 | -0.0183 | -0.02 | 0.19 | 0.08 | -0.03 | 0.46 | 0.09 |
| Surprise Percentage | -40.8451% | -21.0896% | 12.0482% | 14.8649% | 7.2464% | -1.9503% | -2.0408% | 25.3333% | 8.3333% | -3.2967% | 66.6667% | 16.0714% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.67 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AMPH
2026-05-27 17:39:31
Amphastar Pharmaceuticals, Inc. announced that CFO Bill Peters and EVP of Corporate Administration Jacob Liawatidewi will present at the 2026 Jefferies Healthcare Conference on June 3, 2026. The presentation will be webcast live on the company's website and will be available for 30 days. Amphastar focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, and also sells active pharmaceutical ingredients.
2026-05-27 10:09:44
Amphastar Pharmaceuticals, Inc. announced that CFO Bill Peters and EVP Jacob Liawatidewi will present at the 2026 Jefferies Healthcare Conference on June 3, 2026, at 4:55 p.m. ET. A webcast of the presentation will be available on the company's investor relations website for 30 days. Amphastar is a biopharmaceutical company specializing in generic and proprietary injectable, inhalation, and intranasal products.
2026-05-27 10:09:44
Amphastar Pharmaceuticals, Inc. announced that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will present at the 2026 Jefferies Healthcare Conference on June 3, 2026, at 4:55 p.m. ET. A webcast of the presentation will be available on the company's investor relations website for 30 days. Amphastar is a biopharmaceutical company focused on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products.
2026-05-19 11:40:55
This article lists the best small-cap pharma stocks, focusing on Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH). It details a recent downgrade by Wells Fargo due to revenue trajectory concerns and issues with a potential interchangeability status for AMP-004. Despite this, the company reported strong Q1 2026 results with progress in commercial base strengthening and pipeline advancements, including a new product launch and an exclusive licensing agreement.
2026-05-17 18:09:53
Amphastar Pharmaceuticals reported flat revenue and missed adjusted profit forecasts in Q1 2026, causing a negative stock response. The company attributed these results to persistent price reductions, particularly for its diabetes treatment BAQSIMI, and increased competition. Analysts inquired about BAQSIMI's pricing challenges, timelines for synthetic corticotropin, insulin aspart biosimilar initiatives, and the market potential for new products, alongside concerns about future glucagon sales.
2026-05-17 03:08:59
The pharmaceutical sector experienced mixed Q1 2026 earnings, with overall revenues exceeding analyst estimates by 1.5% but share prices declining by an average of 4.1%. Amphastar Pharmaceuticals reported flat revenues of $171.2 million, missing expectations and leading to a 25.1% stock drop. In contrast, Eli Lilly saw a significant surge, with revenues increasing 55.5% year-over-year to $19.8 billion, greatly surpassing analyst predictions.
